AU2020902702A0 - octanoic acid formulation for the delivery of cannabidiol with multiple usage composition - Google Patents

octanoic acid formulation for the delivery of cannabidiol with multiple usage composition

Info

Publication number
AU2020902702A0
AU2020902702A0 AU2020902702A AU2020902702A AU2020902702A0 AU 2020902702 A0 AU2020902702 A0 AU 2020902702A0 AU 2020902702 A AU2020902702 A AU 2020902702A AU 2020902702 A AU2020902702 A AU 2020902702A AU 2020902702 A0 AU2020902702 A0 AU 2020902702A0
Authority
AU
Australia
Prior art keywords
cannabidiol
delivery
octanoic acid
acid formulation
multiple usage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020902702A
Inventor
Antonio Torres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2020902702A0 publication Critical patent/AU2020902702A0/en
Abandoned legal-status Critical Current

Links

AU2020902702A 2020-08-01 octanoic acid formulation for the delivery of cannabidiol with multiple usage composition Abandoned AU2020902702A0 (en)

Publications (1)

Publication Number Publication Date
AU2020902702A0 true AU2020902702A0 (en) 2020-08-13

Family

ID=

Similar Documents

Publication Publication Date Title
CL2018000705A1 (en) Composicion farmaceutica que comprende un complejo molecular que consiste en acido zoledronico, dl-lisina y agua; forma de dosificacion oral con revestimiento enterico.
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
EP3659585A4 (en) Composition for delivering physiologically active ingredients into blood vessel
EP3890685A4 (en) Compositions comprising benefit agent containing delivery particle
BR112015011516A2 (en) compositions containing succinate dehydrogenase inhibitor
BR112013006341A2 (en) liquid agricultural formulations with improved stability
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NZ630967A (en) C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
BRPI0821474B8 (en) stable liquid pharmaceutical formulation
BR112015022972A2 (en) s-ketamine hydrochloride pharmaceutical composition
CR20160235A (en) TIENOPIRIMIDINS AS MKNK1 AND MKNK2 INHIBITORS
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
BR112016020181A8 (en) choline ester lipoic acid compositions and methods of use.
EP3937905A4 (en) Rinse-off compositions and uses thereof for delivery of active agents
BR112013019394A2 (en) use of an agent
EP3946316A4 (en) Cannabidiol pharmaceutical compositions
WO2013104892A8 (en) Application of high dose compounds via inhalation
EP3932901A4 (en) Isobutyric acid ester compound having n-butyryloxy at alpha-position, perfume composition, and use as perfume
AU2020902702A0 (en) octanoic acid formulation for the delivery of cannabidiol with multiple usage composition
BR112014027653A2 (en) formulations for the release of active ingredients
EP4015042A4 (en) Pharmaceutical composition containing antifungal agent as active ingredient
EP3956429A4 (en) Active composition delivery system
EP3982929A4 (en) Hydrogel drug delivery composition
EP3930700A4 (en) Bis-biguanide compounds, pharmaceutical compositions and uses in managing cancer